Osteo-promoting activity of OSTEOPLANT ANGIOSTAD in vitro.
Minerva Stomatol
; 57(4): 189-98, 2008 Apr.
Article
em En
| MEDLINE
| ID: mdl-18427363
ABSTRACT
AIM:
There is an increasing need for an appropriate and readily-available material to reconstruct large bone defects, one of the most significant problems in the dental and maxillo-facial fields. The in vitro study examines the effects of OSTEOPLANT ANGIOSTAD, a product developed to increase osteoinductivity.METHODS:
The product's biological properties were assessed by examining the viability of cultured bone-marrow mesenchymal stem cells (MSC) through the methylthiazol tetrazolium assay; transforming growth factor (TGF)-b release by these cells through the enzyme-linked immunosorbent assay (ELISA) and the migration capacity of MSC and endothelial cells, by the in vitro wound closure test and transwell-migration assay, respectively.RESULTS:
OSTEOPLANT ANGIOSTAD preserved MSC's viability and improved their capacity to release TGF-b1. It also increased in vitro wound healing by MSC and migration of endothelial cells.CONCLUSION:
The results show that, since it increases the production by MSC of proangiogenic factors such as TGF-beta and promotes endothelial cell migration, OSTEOPLANT ANGIOSTAD may be an appropriate adjunct to accelerate the osteointegration of bone substitutes.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Osteogênese
/
Colágeno Tipo I
Limite:
Humans
Idioma:
En
Revista:
Minerva Stomatol
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Itália